Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Insider Sells $56,475.00 in Stock

Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) insider Reshma P. Shetty sold 37,650 shares of the stock in a transaction on Wednesday, November 8th. The shares were sold at an average price of $1.50, for a total value of $56,475.00. Following the completion of the sale, the insider now owns 12,600,454 shares in the company, valued at approximately $18,900,681. The transaction was disclosed in a filing with the SEC, which is available at the SEC website.

Ginkgo Bioworks Stock Performance

DNA stock opened at $1.35 on Monday. Ginkgo Bioworks Holdings, Inc. has a 52 week low of $1.12 and a 52 week high of $2.86. The company’s 50-day simple moving average is $1.71 and its 200 day simple moving average is $1.76.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in DNA. ARK Investment Management LLC boosted its stake in shares of Ginkgo Bioworks by 7.3% in the third quarter. ARK Investment Management LLC now owns 182,192,185 shares of the company’s stock valued at $329,768,000 after buying an additional 12,442,658 shares during the period. BlackRock Inc. lifted its position in shares of Ginkgo Bioworks by 34.6% during the 2nd quarter. BlackRock Inc. now owns 68,202,832 shares of the company’s stock valued at $126,857,000 after acquiring an additional 17,538,752 shares during the period. Sumitomo Mitsui Trust Holdings Inc. grew its holdings in shares of Ginkgo Bioworks by 15.7% during the 3rd quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 58,746,160 shares of the company’s stock worth $106,331,000 after purchasing an additional 7,958,613 shares in the last quarter. Nikko Asset Management Americas Inc. increased its position in shares of Ginkgo Bioworks by 13.5% in the first quarter. Nikko Asset Management Americas Inc. now owns 42,596,595 shares of the company’s stock worth $55,802,000 after purchasing an additional 5,082,277 shares during the period. Finally, State Street Corp raised its stake in Ginkgo Bioworks by 40.6% in the second quarter. State Street Corp now owns 20,683,752 shares of the company’s stock valued at $38,472,000 after purchasing an additional 5,976,244 shares in the last quarter. 56.84% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several equities analysts have recently weighed in on DNA shares. Raymond James dropped their price objective on shares of Ginkgo Bioworks from $5.00 to $3.50 and set an “outperform” rating on the stock in a research report on Thursday, August 31st. BTIG Research cut Ginkgo Bioworks from a “buy” rating to a “neutral” rating in a report on Thursday. One investment analyst has rated the stock with a sell rating, two have given a hold rating and two have issued a buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $3.44.

About Ginkgo Bioworks

Ginkgo Bioworks Holdings, Inc, together with its subsidiaries, develops platform for cell programming. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. The company serves various end markets, including specialty chemicals, agriculture, food, consumer products, and pharmaceuticals.